By combining with immune checkpoint blockade (anti-PD-L1), the NB-mediated therapy achieved complete regression of the primary tumors and effective inhibition of metastatic tumors in CT26 tumor–bearing mouse models. This evidence concerns the gene CD274 and neoplasm.